Policy
Decolonising cancer research: why it matters, what can be done
When cancer epidemiologist and medical doctor Nirmala Bhoo-Pathy returned to Malaysia in 2011 after completing her PhD in cancer epidemiology in the Netherlands, she hadn’t expected the move to negatively…
Lung cancer screening: time to act on the evidence
“It’s extraordinary that screening for the biggest cancer killer is not available in most of Europe,” says Anne Marie Baird, President of Lung Cancer Europe (LuCE). “Lung cancer causes more…
Trust me: I’m a surgical oncologist!
Surgery has been the mainstay for treating solid tumours since the dawn of cancer treatment, and recent decades have seen a huge increase in the complexity and multidisciplinary demands of…
PSA population screening is back in favour: here’s why
Five years ago, the idea of national screening programmes for prostate cancer had gone cold. The benefits of PSA (prostate specific antigen) blood testing, introduced as a screening tool in…
Older, frail patients are still being let down by the regulators
Hans Wildiers is frustrated. “This drug is well-tolerated in older persons – this is a very frequent conclusion in publications. And it is often not a correct conclusion,” says the…
Not too little, not too much… a lesson for cancer prevention from ancient civilisations
“If we could give every individual the right amount of nourishment and exercise, not too little and not too much, we would have found the safest way to health.” This…
Beating cancer is complex – our messaging must be clear
A window of opportunity is opening up across Europe to reverse the ever-rising trend of new cancers and improve outcomes for patients everywhere. It’s been brought about in part by…
Croatia’s cancer plan showcases the value of European cancer collaboration
Croatia has caught up with the rest of the EU in adopting a national cancer control plan. Sophie Fessl looks at how using EU guidance drawn from experiences of other…
A silver lining: Could changes forced by the pandemic point to better ways to conduct our clinical trials?
Pragmatic adjustments to trial protocols were seen to be essential during the Covid-19 pandemic to avoid trials being abandoned or delayed. Most changes involved reducing the requirements for travelling to…
Could covid-19 boost interest in drug repurposing in oncology?
Could the frantic search for drugs to treat patients severely affected by the covid-19 virus be a shot in the arm for new cancer treatments? There have been many headlines…